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Abstract
Background: The development of total knee replacement (TKR) implant designs aims to improve outcome
regarding pain, function, joint stiffness, instability, patellar problems, and ultimately wear of the implant. Recently,
two major orthopaedic implant manufacturers launched a new generation of TKR implants which, according to the
manufacturers, provide improved functional outcome. However, the benefits of these new TKR designs claimed by
the manufacturers in terms of improved functional outcome still lack scientific documentation. The present
randomized controlled trial has been designed to compare three fixed bearing, cemented cruciate-retaining (CR)
designs; one of the new personalized TKR design with two conventional TKR designs with the main emphasis
being on functional outcome.
Methods: The present study is a prospective, double-blinded, randomized, single-center intervention trial. A total of
240 patients will be recruited to participate in a parallel-group study at Coxa Hospital for Joint Replacement,
Tampere, Finland. We will compare the short-term functional outcome of TKR performed with a novel personalized
TKR design (Persona CR, Zimmer, Warsaw, IN, USA) against TKRs performed with two conventional designs (PFC CR,
DePuy, Warsaw, IN, USA and Nexgen CR, Zimmer, Warsaw, IN, USA). In total, 80 patients will be randomized in each
of the three study arms. The primary outcome in this study is the Oxford Knee Score (OKS), which is a validated
patient-reported outcome measure (PROM). Secondary outcome measures include the Forgotten Joint Score, the
15D, the UCLA activity score, and the VAS pain scale. The results will be analyzed after 2-year follow-up.
Discussion: This paper presents a prospective, randomized, single-center trial study protocol. It provides details of
patient randomization, PROMs, follow-up, methods of analysis of the material, and publication plan. An important
aspect that will be considered in the study will be the economic effects of the novel designs as they are
substantially more expensive, and the benefits of the added costs remain unknown. In addition, it is especially
important to carry out evaluative studies in independent centers that are not biased by the interests of the
manufacturers.
Trial registration: Retrospectively registered, November, 2017, ClinicalTrials.gov Identifier: NCT03339557.
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Background
Total knee replacement operations are well-documented
and effective treatments to decrease pain and improve
function in patients with end-stage arthritis of the knee
joint [1–3]. Moreover, knee replacements have been
shown to be effective both clinically and in terms of cost
effectiveness [4, 5]. Demand for joint replacement opera-
tions has continuously increased, and future projections
suggest that this trend will continue [6], which will pose
increasing demands on health care systems.
Although joint replacement surgery is widely consid-
ered to be one of the success stories of modern medi-
cine, approximately up to 20% of patients with a knee
replacement are to some extent dissatisfied with the out-
come following their joint replacement operation [7–9].
Evaluation of treatment
Measuring the outcome of total knee replacement sur-
gery is challenging. Earlier, implant survival, i.e., the ab-
sence of revision surgery, was the most referenced
measure of success. With contemporary implants and
surgical techniques, the survival of most knee implants
has been shown to be excellent even in long-term
follow-up, as reported by many national joint registries
[10–14]. Moreover, most implant designs have cumula-
tive revision rates below 1% per annum, a target level set
by the National Institute of Healthcare and Clinical Ex-
cellence (NICE) [15]. Recently, however, more emphasis
has been put on patient satisfaction. Patient reported
outcome measures scores (PROMs) have been intro-
duced and used instead of traditional surgeon-based
clinical assessments [16, 17]. One of the most widely
used PROMs is the Oxford knee score (OKS), which is
also included in the National Joint Registry for England
and Wales data as an outcome measure [11, 18]. Other
commonly used PROMS include the Visual Analogue
Scale (VAS), the health-related quality of life (15D), and
the UCLA activity score [19, 20]. At present, however,
there is no single score or method for the assessment of
all outcome aspects with widespread agreement, and
newer and more sensitive scores, such as the “Forgotten
joint score” (FJS), have been introduced to better capture
the differences in function after TKR in more active pa-
tients [21–23].
Previous studies
In addition to the patient related factors, surgical tech-
nique as well as the knee replacement design used influ-
ence the outcome [24] . Based on large registry data, it
has been postulated that the effect of surgical factors, in-
cluding implant type, are modest when compared with
patient related factors [25].
The significance of implant design on knee function has
been widely studied [26–29], as there is broad variability
in implant concepts and specific designs. Numerous stud-
ies, however, have been unable to detect any differences in
function between the most commonly used cruciate
retaining (CR) or substituting, posterior stabilised (PS)
concepts [26, 28]. Using the OKS as an outcome measure,
one registry-based study showed that the performance of
one implant type was statistically significantly better than
all of the other most used contemporary implant designs
[24]. However, the differences between the groups were
not even close to the recently described minimally clinic-
ally important difference [30]. On the other hand, one
small study showed that refining a well performing knee
design did not influence the functional outcome [31] . In
contrast to this finding, a new design was reported to im-
prove the OKS score of TKR patients in a cross-sectional
setting [32]. However, due to obvious limitations in study
settings, these results must be interpreted with caution.
The effect of implant design on the outcome of knee
replacement surgery is clearly being emphasized by the
implant manufacturing industry. New, personalized and
hopefully improved implant designs are the target of in-
tensive research and development projects. A more ana-
tomically accurate implant, finer sizing increments and
full continuum of bearing constraints is redefining
personalization. Recently, two major orthopaedic im-
plant manufacturers both launched a new generation
total knee replacement implant on to the market. Both
of these implant systems are based on the legacy of their
predecessors, which have been among the most im-
planted and best-documented designs globally. The
clearly stated aim of these new systems is to improve
functional outcome with less pain, joint stiffness, in-
stability, patellar problems, and ultimately wear of the
implant. However, the benefits claimed for these new or
redesigned models in terms of improved outcome still
lack scientific documentation. Cost is also an important
aspect as the novel designs are substantially more expen-
sive, and therefore the benefits of the added costs remain
unknown. Furthermore, it is especially important to
carry out evaluative studies in independent centers that
are not biased by the interests of implant manufacturers.
Study objective
The aim of this randomized controlled trial is to compare
one novel, personalized TKR implant design (Persona CR,
Zimmer, Warsaw, IN, USA) against two conventional TKR
design (PFC CR,DePuy, Warsaw, IN, USA and NexGen
CR, Zimmer, Warsaw, IN, USA) in terms of functional out-
come and cost-effectiveness.
Methods
The study design is a prospective, double-blinded ran-
domized controlled, single-center trial adhering to Stand-
ard Protocol Items: Recommendation for Interventional
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Trials (SPIRIT) guidelines. The study will be carried out at
Coxa Hospital for Joint Replacement (Tampere, Finland),
a university-affiliated publicly-funded orthopaedic hospital
specializing in joint replacement surgery. Currently, more
than 4000 joint replacements are performed annually
(representing approximately 20% of all hip and knee re-
placements performed annually in Finland), of which 2000
are primary knee replacement operations. Coxa Hospital
is responsible for joint replacement surgery in Pirkanmaa
Hospital District with a catchment area population of ca.
550,000 inhabitants, and it also serves as a tertiary referral
hospital for one-fifth of Finland.
Primary and secondary outcome measures
The primary outcome is the Finnish language version of the
OKS (33) measured both preoperatively, and postoperatively
at 2–3, 12, and 24months. The OKS is a validated and reli-
able PROM. The questionnaire comprises 12 items regard-
ing pain and activities of daily living (ADL) specifically
related to the knee. Each item is scored on a five-level Likert
scale 0 (worst disability) to 4 (no disability). The total score
can range from 0 to 48, with 48 being the best possible
score. The minimal clinically important difference (MCID)
depends on the purpose of the comparison: it has recently
been defined as 5 points, when different patient cohorts are
compared against each other [18, 30, 33, 34]. Thus, in this
study, a > 5-point difference in median OKS at 24months
postoperatively between any of the three cohorts studied
(Persona CR, PFC CR, and NexGen CR) will be defined as a
clinically significant difference in functional outcome.
The secondary measured outcomes both preopera-
tively, and after surgery at 2–3, 12, and 24 months are
the FJS, the 15D, the UCLA activity score, and the VAS
pain scale.
The FJS is an assessment tool designed especially for
well-performing patients and describes the patients’ abil-
ity to forget the artificial joint in everyday life. The ques-
tionnaire comprises 12 items regarding and integrating
pain, stiffness, function in ADL, patients’ activity levels,
and psychosocial factors. Each item is scored on a five-
point Likert response format of 1 (never) and 5 (mostly),
and scores are summed and linearly transformed to a 0
to 100 scale. The high scores indicate good outcome,
equaling a high degree of forgetting the replaced joint
during ADL [17, 22, 35]. The validity and reliability of
the FJS has been reported to be good, with a lower ceil-
ing effect than the OKS [36].
The 15D is a generic, comprehensive (15-dimensional)
self-administered instrument for measuring health-related
quality of life (HRQoL)(19). The questionnaire comprises
15 dimensions with 5 ordinal levels on each dimension.
From each dimension, the respondents choose the level
that best describes their present health status. A set of
population-based preference and utility weighs is used to
generate the 15D score on a 0 (being dead) to 1 (full health)
scale. Moreover, the 15D scores are generalizable and valid
for deriving quality-adjusted life years (QALYs). The gen-
eric MCID for the change of 15D scores are ±0.15 [19, 37].
The 10-point University of California Los Angeles
(UCLA) activity score has 10 descriptive activity levels
ranging from wholly inactive (level 1) to regular partici-
pation in impact sports (level 10) [20].
The visual analogue scale (VAS) pain score, compris-
ing a scale from 0 (no pain) to 10 (worst imaginable
pain), is used to evaluate pain. In cost-effectiveness ana-
lysis, cost of surgery, hospitalization, out-patient visits
and physiotherapy visits will be calculated. Cost per
quality-adjusted life-years will be analyzed.
To further analyze the differences and complex relation-
ships between pain experience and joint function, a sam-
ple of synovial tissue will be analyzed for patient specific
factors associated with inflammation and inflammatory
pain. These analyses will include immunohistology and
measurements of gene expression and polymorphism re-
lating to modulating pain and inflammatory reaction.
Hypotheses
Our primary hypotheses in the study are the following:
i. The two conventional TKR implant designs and the
novel implant design will yield similar functional
outcomes measured with OKS
ii. Total knee replacement with either of the two
conventional TKR implant designs will be more
cost-effective than TKR with the novel implant
design regarding quality-adjusted life years
(QALYs) measured with the 15D
iii. High pain sensitivity will be associated with poor
functional outcome irrespective of the implant
design or radiographic severity of knee
osteoarthritis (OA).
Patient recruitment
Patients will be recruited from Coxa’s outpatient clinic
according to our inclusion and exclusion criteria. The
participating orthopaedic surgeons will recruit patients
alongside their routine out-patient work. Written in-
formed consent will be obtained. In the study, the indi-
cations for surgical treatment will follow the routine
clinical guidelines of the hospital (Fig. 1).
Patient inclusion criteria
 patients undergoing total knee replacement
surgery for primary knee OA
 no previous open major surgery in the joint
(e.g., osteotomy)
 age 50–70 years
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 unilateral operative treatment with no plans for
surgical treatment of the contralateral knee in the
near future
 patients living in the local hospital district
(Pirkanmaa Hospital District)
 Kellgren-Lawrence grade 3–4 knee osteoarthritis in
plain radiographs
Patient exclusion criteria
 unwilling to provide informed consent
 > 15 degrees varus or valgus, or > 15 degrees fixed
flexion deformity
 predominantly patellofemoral osteoarthritis
 Physical, emotional, or neurological conditions that
would compromise the patient’s compliance with
postoperative rehabilitation and follow-up (e.g., drug
or alcohol abuse, serious mental illness, general
neurological conditions, such as Parkinson, MS, etc.)
Patient randomization
When TKR surgery is decided, the eligible patients will
be informed and those willing to participate will be ran-
domized into one of the three implant groups. Block
randomization lists will be computer-generated. Block-
size will be variable with equal allocations to the three
study groups. Numbered, sealed envelopes will be pre-
pared. The trial coordinator will open the next (in num-
ber) sealed randomization envelope pre-operatively and
reveal allocation. Opening of the envelope will be done
after the surgeon has ascertained that the patient meets
the eligibility criteria and that all of the implant types
are feasible for the patient. The allocated implantation
will then be performed, and the envelope, with study
number indicated, returned to the trial coordinator.
Preoperative patient evaluation
The preoperative medical history will be carefully docu-
mented according to routine screening for TKR surgery.
The preoperative planning will include plain radiographs
of the operated knee and standing long axis radiograph
of the affected limb. Specific attention will be paid to
record history of chronic pain, long- standing pain medi-
cation, a history of fibromyalgia, depression, anxiety, or
other mental disturbances.
In addition to our normal preoperative protocol (in-
cluding OKS), the patient will be asked to complete the
following questionnaires/tests: the 15 D, the UCLA ac-
tivity score, the FJS, and questionnaires for pain sensitiv-
ity and brief pain inventory.
Operative treatment
Patients will be operated upon using the implant allo-
cated in the randomization. Perioperative treatment
will be carried out according to the routine protocol
of the hospital: total knee arthroplasties (TKA) will be
performed using the medial parapatellar approach,
and the decision to use / not to use a tourniquet will
be based on the surgeon’s preference. The mechanical
alignment [38] technique will be used. The measured
resection [39] technique, a combination of bony land-
marks (femoral epicondyles, posterior condylar axis,
Fig. 1 Patient flow through the trial (PROM: Patient Reported Outcome Measures)
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and anterior-posterior axis), will be used to determine
proper rotation of the femoral component. Distal fem-
oral resections will be performed first using an intra-
medullary guide, which will be followed by a posterior
referencing cutting block used to identify the proper
component size. An appropriate 4-in-1 resection block
will be used to perform anterior, posterior, and cham-
fer bone cuts in the femur. An extramedullary align-
ment guide will then be used to perform the tibial cut.
Soft-tissue balance will be evaluated using either dir-
ectly trial components or by first assessing ligament-
ous and gap balance with a tenser-device. Again, this
will be based on the individual surgeon’s preferences.
With trial components, range of motion, ligamentous
balance, as well as extension-flexion gaps will be al-
ways assessed and recorded by the operating surgeon.
If necessary, soft-tissue releases and ligament balan-
cing will be performed to balance gap differences and/
or varus/valgus ligamentous balance. All components
implanted will be cemented, and the patella will only
be resurfaced if there is a problem with patellar track-
ing. The TKAs will be carried out under spinal
anesthesia in combination with intravenous sedation.
General anesthesia will only be used if there is a
contraindication to spinal anesthesia. Immediate full
weight bearing will be allowed, and all patients will be
mobilized on the day of the surgery. Antithrombotic
prophylaxis, with low molecular-weight heparin, enox-
aparin will be administered for 3 to 4 weeks postopera-
tively. All details of perioperative care and possible
complications will be recorded in the hospital’s elec-
tronic database in a routine manner.
A 10 g sample of synovial tissue will be obtained dur-
ing surgery. The study protocol will not require any add-
itional tissue removal during surgery.
Postoperative follow-up
The first postoperative visit to a physiotherapist blinded
to the allocation will take place at 2 to 3 months after
surgery. This visit will include a routine physical exam-
ination, plain radiographs of the operated joint, and the
OKS score. In addition, the screening questionnaires/
tests will be repeated, as described in Table 1. All com-
plications and re-operations of the operated knee will be
recorded.
The follow-up visits at 1 and 2-year intervals are add-
itional to normal clinical practice. They will be performed
by a physiotherapist blinded to the allocation and will in-
clude repeating the follow-up questionnaires, as shown in
Table 1 The schedule of enrollment, interventions, and assessments
Study period
Enrollment Allocation Post-allocation Close-out
Timepointa -t1 0 t1 t2 t3 t4
Enrollment
Eligibility screen X
Informed consent X
Medical history X
Allocation X
Interventions:
PFC CR Total knee replacement X
NexGen CR Total knee replacement X
Persona CR Total knee replacement X
Assessments:
X-ray X X
Pain sensitivity (PCS) X
Pain inventory (BPI) X
Oxford Knee Score (OKS) X X X X
15D X X X X
Forgotten Joint Score (FJS) X X X X
UCLA activity score X X X X
Surgeon visit X
Physiotherapist visit X X X X
a-t1 = baseline, t1 = operative treatment, t2 = postoperative at 2–3 months, t3 = at 1 year, t4 = at 2 years
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Table 1. All complications and re-operations of the stud-
ied knee will be recorded.
Further to the present work-flow, follow-up visits will
be planned to take place at 5, 10, 13, and 16 years from
the index operations to assess the mid- to long-term
outcome and implant survivorship.
Sample size
The power analyses will be calculated using both the
OKS (primary outcome) and the FJS (secondary out-
come). Of these, the FJS is more sensitive in differentiat-
ing patients at the upper end of the outcome scores and
requires larger patient groups. With the OKS, the esti-
mated sample size is 48 patients per arm. With the FJS
in the range of 60 to 80 and a standard deviation of 25
points, the estimated sample size is 64 patients per arm
(delta = 13, sd = 25, alpha = 0.05, power = 0.8). Allowing
for a 10% drop-out rate and a 10% addition due to skew-
ness in the variable distribution, the required arm size is
80. Therefore, with three comparison arms, the total
number of patients recruited into the study will be 240.
Blinding
Participants will be blinded to the implant design used
in their operation. Staff on the ward will also be blinded.
The physiotherapists conducting the follow-up visits (at
2–3 months, 1 year, and 2 years, i.e., the outcome asses-
sors) will also be blinded to the allocation. The patients
will not receive information on the specific implant de-
sign used in their operation until all patients have com-
pleted the 2-year follow-up visit.
Statistical methods
Descriptive statistics, including mean and standard devi-
ation, for continuous variables will be used. Differences
between groups in continuous skewed main outcome
variables will be analyzed using the Mann-Whitney U-
test, and t-test when variables are normally distributed.
Results will be presented with 95% confidence intervals.
Two-way-tables with the chi-square test will be used for
dichotomous variables, and multivariate analysis will be
conducted with regression analysis. The α-level will be
set at 0.05. SPSS Statistics version 23 (IBM Corp.,
Armonk, NY) will be used for the analysis.
Study material
All the information and gathered material will be stored
in a study registry at Coxa Hospital for Joint Replace-
ment. The registry will be protected with passwords that
will only be given to the authors and the secretary of the
study group. All study data will be deleted 15 years after
the end of the study, as required by Finnish law.
Time schedule
Recruitment for the study began in September 2015 and
was completed in August 2018. The results of the study
will be analyzed after 2-year follow-up, and the final re-
port will be published by the end of 2021.
Discussion
This paper presents a prospective, randomized con-
trolled trial comparing a novel TKR implant design with
conventional TKR designs in terms of functional out-
come and cost-effectiveness. It describes details of pa-
tient randomization, PROMs, follow-up, aftercare and
methods of analysis of the material, and publication
plan. The strengths of our study include its pragmatic
nature and validated outcome measures, with an em-
phasis on PROMS. We included several aspects of out-
come to capture the whole picture of patient satisfaction
and to obtain data on the economic aspect for cost/
benefit analyses.
The adequate number of patients is a very critical
question. According to power analysis, our study design
allows us to have sufficient numbers of patients to con-
firm or reject the research hypotheses on primary out-
come measures. This is especially important if the
results turn out to show no differences between the
study arms – to avoid speculation on the possibility of a
type 2 error. The economical aspect is also important as
the novel designs are substantially more expensive, and
therefore the benefits of the additional costs are of great
interest to all health care providers.
Maintaining blinding of study arms is challenging in
all studies that assess the outcomes of surgical proce-
dures. Successful blinding of the patients is critical be-
cause PROMS are the key outcome tools. We discussed
the nature and importance of blinding with the patients
before they consented to participate in the study. The
follow-up visits are being carried out by physiotherapists
who are dedicated to research projects, and their perfect
blinding is also challenging and depends largely on their
commitment to the study philosophy.
Strict inclusion criteria are a possible limitation of our
study and may result in selection bias, as a good number
of patients had to be excluded. Therefore, even random
allocation may end up in heterogeneity of intervention
arms. However, the inclusion criteria are set to focus on
the most common type of patient, i.e., patients with pri-
mary uncomplicated osteoarthritis of the knee. The
upper age limit was set to 70 years to also obtain out-
come data on the more active younger TKR patients,
who tend to end up at the upper end of the outcome
scores after TKR surgery. In theory, this approach might
help us to better differentiate “good” outcome from an
“excellent” outcome, especially if such subtle differences
are found between the implant designs that would not
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become evident in the older, less active patient groups.
On the other hand, if a novel knee design cannot pro-
vide these younger and generally more active patients
with an improved functional outcome, it will certainly
not do so in other patient groups either.
Introducing a new TKR implant system is a known risk
factor for failure in joint replacement [40]. This poses the
danger of a type 2 error in hypothesis 1, as the surgeons
are more familiar with the conventional implant systems
and the outcome of the novel TKR design may be inferior
due to surgeon-related factors. To avoid this pitfall, we ar-
ranged a formal training of the novel implant system and
allowed each of the participating surgeons to perform ap-
proximately 10 surgeries with the novel implant before
commencing the random allocation.
The longevity of contemporary TKR designs is ex-
cellent, but the functional outcome and patient satis-
faction levels still leave room for improvement.
Functional outcome is, however, the result of complex
interplay, where the implant design is only one factor
and patient characteristics and the surgeon perform-
ing the implantation play major roles as well. The de-
velopment of TKR implants is a continuous activity,
where the manufacturing industry plays a leading role.
The evaluation of novel designs must be carried out
according to strict scientific methods to be able to
differentiate the influence of the three major factors
– the implant, the patient, and the surgical perform-
ance – from each other. In addition, it is especially
important to carry out these evaluative studies in in-
dependent centers, and not to be biased by the inter-
ests of implant manufacturers.
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